Post-Doctoral Fellow Position at Shanghai Institute of Materia Medica/Suzhou Xenofinder
Post-Doctoral Fellow Position at Shanghai Institute of Materia Medica / Suzhou Xenofinder
Post-Doctoral Fellow Position at Shanghai Institute of Materia Medica / Suzhou Xenofinder
Skills, Experience, Qualifications, If you have the right match for this opportunity, then make sure to apply today.
Xingxing Diao received his PhD from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (Shanghai, China) in 2014 and completed his postdoctoral training in NIH (Baltimore, USA) in 2014-2016.
He then worked in XenoBiotic Laboratories (Plainsboro, NJ, USA) and Celgene (Summit, NJ, USA) for 3 years prior to returning to China.
In addition to leading XenoFinder, Dr. Diao is currently a professor at SIMM, where he established a comprehensive DMPK lab capable of conducting in vitro and in vivo metabolite profiling and identification, metabolizing enzyme phenotyping, animal PK, radiolabeled ADME studies in animals and human.
His PhD research focused on evaluating DMPK of 3-n-butylphthalide (NBP) in human, including human samples Met ID, quantification of NBP and 4 major metabolites, the metabolic bioactivation underlying the hepatotoxicity of NBP and the mechanism responsible for the isomer-selective distribution of 3-OH-NBP and 10-OH-NBP across blood-brain barrier.
In NIH, he set up human hepatocyte incubation platform to study metabolism of new synthetic cannabinoid (SC) and developed strategies to analyze the use of new SCs for forensic investigation.
In XenoBiotic Laboratories and Celgene, he conducted mainly biotransformation studies of new drug candidates, including metabolite profiling and identification using LC-HRMS and 14C-labeled ADME studies animals and human.
In SIMM, Dr. Diao trains PhD candidates and postdocs, conducts mechanistic studies of drug biotransformation and investigative ADME research of new drug candidates.
Dr. Diao published over 43 peer-reviewed research papers (29 papers are the first-author or corresponding author). (https : / / pubmed.
ncbi.nlm.nih.gov / ?term Xingxing+Diao )
Dr. Mingshe Zhu is an independent consultant to provide DMPK consultation services to biotech and pharma companies in China and USA (Mar 2017-present) in support of drug discovery, development, and regulatory submissions.
He also served as the scientific advisor of DMPK Dept. at WuXi AppTec in Nanjing, China (Mar 2017-Dec 2021) with responsibilities of staff scientist training, developing new methods in ADME studies, technic marketing, key experimental design, data interpretation, and helping clients to solve program issues.
He has involved in IND-enabling biotransformation and radiolabeled ADME studies in animals and human, which supported IND filing of many clinical candidates and NDA filings of over 10 drug candidates in China and USA, including the marketing approval of 5 new drugs (Anlotin, Ensartinib Hydrochloride, Fospropofol Disodium, Donafenib, Olverembatinib) in China.
Dr. Zhu previously worked in Dept. of Biotransformation, Bristol-Myers Squibb (BMS) for 19 years, where he and his team supported over 10 discovery programs, more than 15 development drug candidates, and the worldwide approvals of ABILIFY (Aripiprazole) and FORXIGA (Dapagliflozin).
Dr. Zhu and his collaborators at BMS developed several innovative LC / MS workflows and data-mining technologies such as Mass Defect Filter, Background Subtraction and Multiple Reaction Monitoring for drug metabolite detection and identification, which are now routinely used in drug metabolism research worldwide.
Recently, his research interests have been expanded to unconventional drug modalities, such as ADC, cyclic peptides, herbal medicines, covalent drugs, stable isotope labeled drugs, prodrugs, and protein therapeutics.
He received PhD in analytical toxicology atSUNY Albany and completed post-doctoral fellowship in drug metabolism at University of Washington.
Dr. Zhu served the chair of ISSX focus group of Bioanalysis in ADME Science (2016-2018) and taught drug metabolism and mass spectrometry short courses at ASMS (2011-present), EAS (2002-2010) and ACS (2006, 2008).
He co-edited two books, Drug Metabolism in Drug Design and Development and Mass Spectrometry in Drug Metabolism and Disposition and co-authored 100+ research articles (https : / / pubmed.
ncbi.nlm.nih.gov / ?term Mingshe%20Zhu&sort date ).
J-18808-Ljbffr